What Causes Persistently Elevated ALT and AST?

Answer in brief: Persistent aminotransferase elevation reflects hepatocellular injury but is not a diagnosis. Common causes include MASLD, alcohol-associated liver disease, chronic viral hepatitis, medications/supplements and autoimmune hepatitis; less common causes include hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency and muscle disease. Evaluation should be driven by the pattern, magnitude and duration of abnormality, patient age, metabolic risk, alcohol exposure, medications and associated laboratory findings.

Key clinical points

Confirm persistence and review the laboratory reference range.
ALT/AST pattern is less important than the entire clinical context.
AST can arise from muscle; check CK when muscle injury is plausible.
Persistent unexplained elevation warrants etiologic testing and fibrosis assessment.

Start with pattern and context

ALT and AST are markers of cell injury. ALT is more liver-specific; AST is also present in skeletal muscle and other tissues. Mild chronic elevations are commonly caused by MASLD or alcohol, whereas very high values raise concern for acute viral, ischemic, toxic or autoimmune injury.

History is high yield

Quantify alcohol in standard drinks, review prescribed drugs, over-the-counter products and supplements, ask about metabolic risk, travel, transfusion and viral exposure, and assess symptoms of autoimmune or hereditary disease. Medication timelines matter more than simply finding a drug that is “known to affect the liver.”

Laboratory workup

Common first-line tests include hepatitis B and C serology, iron studies and metabolic assessment; autoimmune markers, ceruloplasmin or alpha-1 antitrypsin testing are added when appropriate. Ultrasound can assess steatosis and biliary/structural disease. Persistent elevation in a patient with metabolic risk should trigger fibrosis stratification with FIB-4 and, when indicated, elastography.

When biopsy enters the picture

Biopsy is not the first test for mild aminotransferase elevation. It becomes useful when the diagnosis remains unclear, noninvasive tests are discordant, autoimmune hepatitis is suspected, or histologic staging would change therapy.

Practical approach

1. Define the liver-disease phenotype and metabolic/alcohol/medication context.

2. Use FIB-4 as first-line fibrosis triage when appropriate.

3. Escalate to VCTE/ELF or other testing when risk is indeterminate or high.

4. Refer or biopsy when noninvasive tests conflict, advanced disease is likely or diagnosis remains uncertain.

Common errors to avoid

Treating FIB-4 or elastography as a stand-alone diagnosis.
Interpreting noninvasive fibrosis tests during acute illness without context.

Trainee takeaway

Persistent aminotransferase elevation reflects hepatocellular injury but is not a diagnosis. The examination question is usually less about memorizing one cutoff than recognizing which finding changes the next clinical decision.

Relevant free books by Dr. Alan B. R. Thomson

Thomson ABR. Mastering the Boards and Clinical Examinations in Internal Medicine: Hepatology. CAPstone Academic Publishers; 2016. ISBN 978-1519751195.
Thomson ABR. The Physiology and Pathophysiology of Gastrointestinal and Hepatopancreaticobiliary Disorders. CAPstone Academic Publishers; 2014. ISBN 978-1500298265.

Free downloads: https://giandhepatology.com/free-medical-books-on-gastroenterology-and-hepatology

Frequently asked questions

Can significant liver disease exist with normal ALT?

Yes. Normal enzymes do not exclude advanced MASLD, chronic hepatitis or cirrhosis.

Does AST greater than ALT prove alcohol-associated liver disease?

No. The pattern can support the diagnosis in context but is neither sensitive nor specific enough to stand alone.

References

1. Thomson ABR. Mastering the Boards and Clinical Examinations in Internal Medicine: Hepatology. CAPstone Academic Publishers; 2016. ISBN 978-1519751195.

2. Thomson ABR. The Physiology and Pathophysiology of Gastrointestinal and Hepatopancreaticobiliary Disorders. CAPstone Academic Publishers; 2014. ISBN 978-1500298265.

3. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797-1835. doi:10.1097/HEP.0000000000000323.

Editorial note: This educational article synthesizes Dr. Thomson’s teaching framework with current society guidance. Recommendations should be checked against the latest guideline, local formulary, regulatory labeling and the individual clinical context before patient-specific use.